MCID: CTN003
MIFTS: 48

Cutaneous Lupus Erythematosus malady

Categories: Rare diseases, Immune diseases, Skin diseases

Aliases & Classifications for Cutaneous Lupus Erythematosus

Aliases & Descriptions for Cutaneous Lupus Erythematosus:

Name: Cutaneous Lupus Erythematosus 12 50 14
Lupus Erythematosus, Cutaneous 50 69
Lupus Erythematosus Cutaneous 52

Classifications:



External Ids:

Disease Ontology 12 DOID:0050169

Summaries for Cutaneous Lupus Erythematosus

Disease Ontology : 12 A lupus erythematosus that causes skin lesions on parts of the body that are exposed to sunlight.

MalaCards based summary : Cutaneous Lupus Erythematosus, also known as lupus erythematosus, cutaneous, is related to epidermolysis bullosa and subacute cutaneous lupus erythematosus, and has symptoms including exanthema and pruritus. An important gene associated with Cutaneous Lupus Erythematosus is CXCR3 (C-X-C Motif Chemokine Receptor 3), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Influenza A. The drugs Hydroxychloroquine and Hormone Antagonists have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and breast, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and hematopoietic system

Related Diseases for Cutaneous Lupus Erythematosus

Diseases in the Cutaneous Lupus Erythematosus family:

Subacute Cutaneous Lupus Erythematosus

Diseases related to Cutaneous Lupus Erythematosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 164)
id Related Disease Score Top Affiliating Genes
1 epidermolysis bullosa 29.5 CXCR3 IL18 TNF
2 subacute cutaneous lupus erythematosus 12.5
3 lupus erythematosus tumidus 11.6
4 lupus erythematosus 11.1
5 tau syndrome 10.3 IL18 TNF
6 t-cell prolymphocytic leukemia 10.2 CXCR3 TNF
7 systemic lupus erythematosus 10.2
8 severe hemophilia a 10.2 EEA1 TNF TRIM21
9 psoriatic arthritis 10.2 IL18 TNF
10 hypotrichosis-lymphedema-telangiectasia-renal defect syndrome 10.2 SELE TNF
11 adamantinoma of long bones 10.1 TRIM21 TROVE2
12 tricuspid valve disease 10.1 TRIM21 TROVE2
13 fibrous histiocytoma 10.1 ICAM1 TRIM21
14 vasculopathy, retinal, with cerebral leukodystrophy 10.1 MX1 TREX1 TRIM21
15 hypopyon ulcer 10.1 ICAM1 SELE
16 macrodactyly of the foot 10.1 ICAM1 SELE
17 facial nerve neoplasm 10.1 CD40LG TRIM21
18 chlamydia 10.1 CD40LG EEA1
19 partial sensory epilepsy 10.1 CD40LG TRIM21
20 dermatomyositis 10.1
21 anaplastic large cell lymphoma 10.1 ICAM1 KRT15 TNF
22 spastic ataxia 7, autosomal dominant 10.1 CD40LG TRIM21
23 submandibular gland disease 10.1 CD40LG TNF
24 venezuelan hemorrhagic fever 10.1 CXCR3 ICAM1 TNF
25 esophageal candidiasis 10.0 CXCR3 ICAM1 TNF
26 hemangioma of orbit 10.0 CD40LG TNF
27 infundibulocystic basal cell carcinoma 10.0 CD40LG MX1
28 dermatitis herpetiformis 10.0 CD40LG TNF
29 spotted fever 10.0 CD40LG TNF
30 hydronephrosis 10.0 CD40LG EEA1
31 tick paralysis 10.0 ICAM1 SELE
32 egg allergy 10.0 CD40LG IL18
33 right ventricle hypoplasia 10.0 ICAM1 SELE TNF
34 erb-duchenne and dejerine-klumpke palsies 10.0 ICAM1 SELE TNF
35 arthritis 10.0
36 discoid lupus erythematosus 10.0
37 cervix small cell carcinoma 10.0 ICAM1 SELE TNF
38 latent syphilis 10.0 CXCR3 ICAM1
39 israeli tick typhus 10.0 CD40LG SELE
40 respiratory system disease 10.0 CD40LG TNF TRIM21
41 rheumatoid arthritis 10.0
42 psoriasis 10.0
43 neonatal jaundice 10.0 ICAM1 IL18 MX1 TNF
44 membranoproliferative glomerulonephritis 10.0 CD40LG TNF TRIM21
45 facial paralysis 10.0 CD40LG IL18
46 trichuriasis 10.0 CD40LG MX1
47 intracranial hemorrhage in brain cerebrovascular malformations 10.0 CD40LG IL18 TNF
48 mast-cell leukemia 9.9 CXCR3 ICAM1 MX1 TNF
49 retinal ischemia 9.9 CXCR3 ICAM1 IL18 TNF
50 benign eccrine breast spiradenoma 9.9 CXCR3 ICAM1 IL18 TNF

Graphical network of the top 20 diseases related to Cutaneous Lupus Erythematosus:



Diseases related to Cutaneous Lupus Erythematosus

Symptoms & Phenotypes for Cutaneous Lupus Erythematosus

UMLS symptoms related to Cutaneous Lupus Erythematosus:


exanthema, pruritus

GenomeRNAi Phenotypes related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.32 CD40LG ICAM1 IL18 MX1 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.32 CD40LG ICAM1 IL18 MX1 TNF

MGI Mouse Phenotypes related to Cutaneous Lupus Erythematosus:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.91 CD40LG CXCR3 ICAM1 IL18 SELE TNF
2 cardiovascular system MP:0005385 9.87 CD40LG CXCR3 ICAM1 IL18 SELE TNF
3 immune system MP:0005387 9.81 TREX1 TRIM21 TROVE2 CD40LG CXCR3 ICAM1
4 integument MP:0010771 9.56 CD40LG ICAM1 IL18 SELE TNF TREX1
5 mortality/aging MP:0010768 9.28 CD40LG CXCR3 ICAM1 IL18 SELE TNF

Drugs & Therapeutics for Cutaneous Lupus Erythematosus

Drugs for Cutaneous Lupus Erythematosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydroxychloroquine Approved Phase 4,Phase 3 118-42-3 3652
2 Hormone Antagonists Phase 4
3 Hormones Phase 4
4 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
5 Anti-Infective Agents Phase 4,Phase 3,Phase 2
6 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Immunosuppressive Agents Phase 4,Phase 2,Phase 1
8 Angiogenesis Inhibitors Phase 4,Phase 2
9 Angiogenesis Modulating Agents Phase 4,Phase 2
10 Anti-Bacterial Agents Phase 4,Phase 2
11 Antimalarials Phase 4,Phase 3
12 Antiparasitic Agents Phase 4,Phase 3
13 Antiprotozoal Agents Phase 4,Phase 3
14 Adrenocorticotropic Hormone Phase 4
15 beta-endorphin Phase 4
16 Melanocyte-Stimulating Hormones Phase 4
17 Omega 3 Fatty Acid Nutraceutical Phase 4
18 Dermatologic Agents Phase 3,Phase 2
19 Protective Agents Phase 3
20 Radiation-Protective Agents Phase 3
21 Sunscreening Agents Phase 3
22
Etanercept Approved, Investigational Phase 2 185243-69-0
23
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
24
Dimethyl fumarate Approved, Investigational Phase 2 624-49-7 637568 5271565
25
Apremilast Approved, Investigational Phase 1, Phase 2 608141-41-9 11561674
26
belimumab Approved Phase 2 356547-88-1 5957 10451420
27
Mycophenolate mofetil Approved, Investigational Phase 2 128794-94-5 5281078
28
Mycophenolic acid Approved Phase 2 24280-93-1 446541
29
Alitretinoin Approved, Investigational Phase 2 5300-03-8 444795
30
Cholecalciferol Approved, Nutraceutical Phase 2 67-97-0 6221 10883523 5280795
31
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 5538
32
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
33
Norflurane Investigational Phase 2 811-97-2
34 Analgesics Phase 2,Phase 1
35 Analgesics, Non-Narcotic Phase 2,Phase 1
36 Anti-Inflammatory Agents Phase 2,Phase 1
37 Anti-Inflammatory Agents, Non-Steroidal Phase 2,Phase 1
38 Gastrointestinal Agents Phase 2
39 Peripheral Nervous System Agents Phase 2,Phase 1
40 Calcineurin Inhibitors Phase 2
41 Phosphodiesterase 5 Inhibitors Phase 1, Phase 2
42 Phosphodiesterase Inhibitors Phase 1, Phase 2
43 Antibodies Phase 2,Phase 1,Early Phase 1
44 Antibodies, Monoclonal Phase 2,Phase 1
45 Immunoglobulins Phase 2,Phase 1,Early Phase 1
46 Antibiotics, Antitubercular Phase 2
47 Bone Density Conservation Agents Phase 2
48 Micronutrients Phase 2
49 Trace Elements Phase 2
50 vitamin d Phase 2

Interventional clinical trials:

(show top 50) (show all 71)
id Name Status NCT ID Phase
1 Acthar for the Treatment of Systemic Lupus Erythematosus in Patients With a History of Persistently Active Disease Active, not recruiting NCT01753401 Phase 4
2 Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases Not yet recruiting NCT03122431 Phase 4
3 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
4 Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion Completed NCT01551069 Phase 3
5 Sunscreen RV 2457C in Photoinduced CLE Completed NCT00470912 Phase 3
6 Efficacy of 595 nm Pulsed-dye Laser in Treatment of Discoid Lupus Erythematosus Recruiting NCT03178188 Phase 2, Phase 3
7 The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus Unknown status NCT00797784 Phase 2
8 Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser Completed NCT00523588 Phase 2
9 Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus Completed NCT01294774 Phase 2
10 Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE) Completed NCT00317681 Phase 2
11 To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus Completed NCT01300208 Phase 2
12 Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus Completed NCT01352988 Phase 2
13 Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients Completed NCT00708916 Phase 1, Phase 2
14 Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions Completed NCT01597050 Phase 2
15 A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus Completed NCT01283139 Phase 2
16 Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions Completed NCT00625521 Phase 2
17 Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions (2) Completed NCT00625157 Phase 2
18 A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus Completed NCT00001680 Phase 2
19 Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis Completed NCT01670565 Phase 2
20 Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) Recruiting NCT02847598 Phase 2
21 Safety and Efficacy of Filgotinib and GS-9876 in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE) Recruiting NCT03134222 Phase 2
22 A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE) Recruiting NCT02660944 Phase 2
23 Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus Recruiting NCT02656082 Phase 2
24 TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment Recruiting NCT02711813 Phase 2
25 Phase Ib Study of SC Milatuzumab in SLE Recruiting NCT01845740 Phase 1, Phase 2
26 A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE) Recruiting NCT02975336 Phase 2
27 Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis Recruiting NCT02770170 Phase 2
28 A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus. Active, not recruiting NCT02185040 Phase 2
29 A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus Active, not recruiting NCT02437890 Phase 2
30 Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus Active, not recruiting NCT02265744 Phase 2
31 A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus Not yet recruiting NCT03161483 Phase 2
32 Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus Terminated NCT01407679 Phase 2
33 Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus Terminated NCT01498406 Phase 2
34 A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus Terminated NCT01466725 Phase 2
35 Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva Terminated NCT00308204 Phase 2
36 A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus Completed NCT01702740 Phase 1
37 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Patients Recruiting NCT02927457 Phase 1
38 Autologous Polyclonal Tregs for Lupus Active, not recruiting NCT02428309 Phase 1
39 A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus Terminated NCT01470313 Phase 1
40 Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus Terminated NCT01389895 Phase 1
41 Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus Terminated NCT01164917 Phase 1
42 Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases Terminated NCT00849745 Phase 1
43 Cutaneous Lupus Erythematosus and Elidel Unknown status NCT00222183
44 Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Unknown status NCT00006055
45 IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus Completed NCT01841619 Early Phase 1
46 Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus Completed NCT01629784
47 Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE) Completed NCT00633945
48 Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE) Completed NCT01146444
49 A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers Completed NCT02034344 Early Phase 1
50 Interdisciplinary Study Group of Lupus Erythematosus (ISGLE) Completed NCT00420173

Search NIH Clinical Center for Cutaneous Lupus Erythematosus

Genetic Tests for Cutaneous Lupus Erythematosus

Anatomical Context for Cutaneous Lupus Erythematosus

MalaCards organs/tissues related to Cutaneous Lupus Erythematosus:

39
Skin, T Cells, Breast, Lung, Testes, Neutrophil, Monocytes

Publications for Cutaneous Lupus Erythematosus

Articles related to Cutaneous Lupus Erythematosus:

(show top 50) (show all 709)
id Title Authors Year
1
Dyschromatosis symmetrica hereditaria with cutaneous lupus erythematosus and hyperthyroidism. ( 28496371 )
2017
2
Rowell's Syndrome or subacute cutaneous lupus erythematosus? ( 27978611 )
2017
3
A Cutaneous Lupus Erythematosus-Like Eruption Induced by Hydroxyurea. ( 27813209 )
2017
4
S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). ( 27859683 )
2016
5
Biological therapies in the treatment of cutaneous lupus erythematosus. ( 27687023 )
2016
6
Fumaric acid ester treatment in cutaneous lupus erythematosus (CLE): a prospective, open-label, phase II pilot study. ( 27147621 )
2016
7
Methimazole-induced chronic cutaneous lupus erythematosus. ( 27519167 )
2016
8
Treatment of cutaneous lupus erythematosus: current practice variations. ( 26821963 )
2016
9
Cutaneous lupus erythematosus of elbows: A distinct entity? ( 26952182 )
2016
10
Primary cicatricial alopecia: Lymphocytic primary cicatricial alopecias, including chronic cutaneous lupus erythematosus, lichen planopilaris, frontal fibrosing alopecia, and Graham-Little syndrome. ( 27846944 )
2016
11
Ziprasidone-induced sub acute cutaneous lupus erythematosus. ( 27838681 )
2016
12
Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience. ( 26873674 )
2016
13
Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors. ( 27398293 )
2016
14
Rare Occurrence of Drug Induced Subacute Cutaneous Lupus Erythematosus with Leflunomide Therapy. ( 27891379 )
2016
15
Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients. ( 26910509 )
2016
16
Anastrozole-induced subacute cutaneous lupus erythematosus. ( 27622265 )
2016
17
The role of Syk in cutaneous lupus erythematosus. ( 26999068 )
2016
18
First case of paraneoplastic subacute cutaneous lupus erythematosus associated with colon cancer. ( 27836354 )
2016
19
Immunomodulation in cutaneous lupus erythematosus subsets. ( 27492812 )
2016
20
Mycophenolate Mofetil in Refractory Cutaneous Lupus Erythematosus: No Definitive Evidence. ( 27587015 )
2016
21
Cutaneous sarcoidosis masquerading as chronic cutaneous lupus erythematosus - case report. ( 27646659 )
2016
22
Advances in the treatment of cutaneous lupus erythematosus. ( 27252259 )
2016
23
Immunogenetics of cutaneous lupus erythematosus. ( 27386968 )
2016
24
Clinical characteristics of cutaneous lupus erythematosus. ( 26985173 )
2016
25
Linear cutaneous lupus erythematosus following the lines of Blaschko - Case report. ( 27579750 )
2016
26
Dermoscopy of subacute cutaneous lupus erythematosus. ( 27260752 )
2016
27
Cutaneous lupus erythematosus induced by golimumab therapy. ( 27458030 )
2016
28
Vitamin D levels in 87 Asian patients with cutaneous lupus erythematosus: a case-control study. ( 27480455 )
2016
29
Cancer risk in cutaneous lupus erythematosus: a population-based cohort study. ( 27520797 )
2016
30
Subacute cutaneous lupus erythematosus. ( 27286780 )
2016
31
The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study. ( 26850655 )
2016
32
A Systematic Review of Patient-Reported Outcomes (PROs) in Patients with Cutaneous Lupus Erythematosus (CLE). ( 27416958 )
2016
33
Pregnancy and contraception in systemic and cutaneous lupus erythematosus. ( 27129743 )
2016
34
Gemcitabine-Induced Subacute Cutaneous Lupus Erythematosus: A Case Report. ( 26928175 )
2016
35
A cross-sectional study of untreated depression and anxiety in cutaneous lupus erythematosus and dermatomyositis. ( 26775780 )
2016
36
The incidence of herpes zoster in cutaneous lupus erythematosus (CLE), dermatomyositis (DM), pemphigus vulgaris (PV), and bullous pemphigoid (BP). ( 27317514 )
2016
37
Toxic Epidermal Necrolysis Like Reaction due to Low-dose Methotrexate in a Case of Cutaneous Lupus Erythematosus: A Rare Occurrence. ( 26955111 )
2016
38
Proton Pump Inhibitor-Associated Subacute Cutaneous Lupus Erythematosus in a Patient With Granulomatosis With Polyangiitis. ( 27870768 )
2016
39
Beside to bench: JAK-inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus. ( 27892610 )
2016
40
Subacute cutaneous lupus erythematosus inducing unilateral sensorimotor neuropathy. ( 27888319 )
2016
41
Apoptosis of keratinocytes and serum DNase I activity in patients with cutaneous lupus erythematosus: relationship with clinical and immunoserological parameters. ( 27557471 )
2016
42
Voriconazole-Induced Subacute Cutaneous Lupus Erythematosus in an Adult With Aspergillosis. ( 28031137 )
2016
43
Bilateral periorbital swelling as the initial presentation of cutaneous lupus erythematosus. ( 27051834 )
2016
44
Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients. ( 27185425 )
2016
45
Effects of hydroxychloroquine on cutaneous lupus erythematosus: A multi-center double-blind randomized parallel-group trial. ( 27992698 )
2016
46
Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus. ( 27270345 )
2016
47
Ethnic differences in the epidemiology of cutaneous lupus erythematosus in New Zealand. ( 27235700 )
2016
48
Cutaneous Lupus Erythematosus: An Update on Pathogenesis, Diagnosis and Treatment. ( 26872954 )
2016
49
Risk of Cerebrovascular Accidents and Ischemic Heart Disease in Cutaneous Lupus Erythematosus: A Population-based Cohort Study. ( 27015109 )
2016
50
Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects. ( 27249209 )
2016

Variations for Cutaneous Lupus Erythematosus

Expression for Cutaneous Lupus Erythematosus

Search GEO for disease gene expression data for Cutaneous Lupus Erythematosus.

Pathways for Cutaneous Lupus Erythematosus

Pathways related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 21)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.06 CD40LG ICAM1 IL18 MX1 TNF TRIM21
2
Show member pathways
12.58 ICAM1 IL18 MX1 TNF
3 12.02 EEA1 IL18 TNF
4
Show member pathways
11.92 IL18 MX1 TNF
5 11.9 CD40LG ICAM1 SELE
6 11.87 ICAM1 SELE TNF
7 11.74 ICAM1 IL18 TNF
8 11.7 ICAM1 SELE TNF
9 11.63 ICAM1 SELE TNF
10 11.59 CD40LG ICAM1 TNF
11 11.53 ICAM1 IL18 TNF
12 11.45 CXCR3 IL18 TNF
13 11.34 CD40LG ICAM1 TNF
14
Show member pathways
11.26 CD40LG ICAM1 SELE TNF
15 11.12 ICAM1 IL18 TNF
16 11 CD40LG IL18 TNF
17 10.97 ICAM1 IL18
18 10.91 IL18 TNF
19 10.8 ICAM1 IL18 SELE TNF
20 10.73 ICAM1 TNF
21 10.71 CD40LG ICAM1 IL18 SELE TNF

GO Terms for Cutaneous Lupus Erythematosus

Cellular components related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 CD40LG CXCR3 ICAM1 TNF

Biological processes related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.58 CD40LG ICAM1 TNF
2 positive regulation of NF-kappaB import into nucleus GO:0042346 9.46 IL18 TNF
3 negative regulation of myoblast differentiation GO:0045662 9.43 IL18 TNF
4 regulation of type I interferon production GO:0032479 9.37 TREX1 TRIM21
5 inflammatory response GO:0006954 9.35 CD40LG CXCR3 IL18 SELE TNF
6 leukocyte tethering or rolling GO:0050901 9.32 SELE TNF
7 regulation of immunoglobulin secretion GO:0051023 9.26 CD40LG TNF
8 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.16 ICAM1 TNF
9 leukocyte cell-cell adhesion GO:0007159 8.8 CD40LG ICAM1 SELE

Molecular functions related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 8.62 CD40LG TNF

Sources for Cutaneous Lupus Erythematosus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....